Spero therapeutics, inc. (SPRO)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17
Cash flows from operating activities:
Net loss

-79,111

-60,925

-46,538

-39,284

-36,090

-41,662

-44,931

-44,312

-44,119

-39,886

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

755

750

1,000

592

498

409

369

382

371

363

0

0

0

Non-cash lease cost

0

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of derivative liabilities

-

-

-

-

-

-

-

-

-

1,541

0

0

0

Share-based compensation

3,953

3,776

3,616

3,340

3,068

2,749

2,353

2,579

1,979

1,427

0

0

0

Realized (gain) loss on investments

-

1

0

0

0

-

-

-

-

-

-

-

-

Unrealized foreign currency transaction (gain) loss

-530

18

-300

-88

-270

-373

0

0

0

-

-

-

-

Accretion of discount on marketable securities

448

750

988

1,120

981

671

0

0

0

-

-

-

-

Changes in operating assets and liabilities:
Other receivables

2,268

7,384

4,681

1,279

-763

-635

-205

566

1,105

707

0

0

0

Prepaid expenses and other current assets

-2,242

-2,654

2,401

4,904

6,549

5,497

73

283

102

575

0

0

0

Tax incentive receivables

-128

-299

529

-963

-753

-770

25

1,619

1,697

1,811

0

0

0

Other assets

4,569

2,912

0

0

0

-

-

-

-

-

-

-

-

Accounts payable

8,396

564

1,131

305

-455

84

373

-516

-38

2,349

0

0

0

Accrued expenses and other current liabilities

7,595

13,610

3,952

367

46

3,575

2,676

366

1,046

1,315

0

0

0

Deferred rent

-

-

-

-

-

554

-124

-125

333

-128

0

0

0

Other long-term liabilities

-107

-52

0

0

0

-

-

-

-

-

-

-

-

Advance payments from collaborator

-

-

-

-

-

-

-

-

-

-

-

-

0

Net cash used in operating activities

-62,425

-50,020

-46,162

-42,017

-38,588

-39,625

0

0

0

-

-

-

-

Cash flows from investing activities:
Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

0

Purchases of marketable securities

67,153

88,993

102,277

140,203

133,185

130,175

0

0

0

-

-

-

-

Proceeds from maturities of marketable securities

100,100

118,837

0

0

0

-

-

-

-

-

-

-

-

Purchases of property and equipment

312

314

0

0

0

-

-

-

-

-

-

-

-

Net cash provided by (used in) investing activities

32,635

29,530

40,916

-15,815

-35,660

-83,156

0

0

0

-

-

-

-

Cash flows from financing activities:
Proceeds from equity offering

-

15,790

0

0

0

-

-

-

-

-

-

-

-

Payment of offering costs

0

-

0

0

0

-

-

-

-

-

-

-

-

Proceeds from stock option exercises

988

508

0

0

0

-

-

-

-

-

-

-

-

Net cash provided by financing activities

44,758

16,140

0

0

0

-

-

-

-

-

-

-

-

Net increase (decrease) in cash and cash equivalents

14,968

-4,350

5,117

22,418

-3,157

-53,258

0

0

0

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

0

Net increase in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

0

Supplemental disclosure of non-cash investing and financing activities:
Purchases of property and equipment included in accounts payable and accrued expenses

-

-

-

-

0

-

-

-

-

-

-

-

-

Offering costs in accounts payable and accruals

0

-

-

-

-

-

-

-

-

-

-

-

-

Conversion of bridge units into preferred units

-

-

-

-

-

-

-

-

-

8,500

0

0

0

Settlement of derivative liabilities upon issuance of preferred units

-

-

-

-

-

-

-

-

-

944

0

0

0

Cumulative dividends on redeemable convertible preferred shares

-

-

-

-

-

-

-

-

-

-

-

-

0

Accretion of redeemable convertible preferred units to redemption value

-

-

-

-

-

-

-

-

-

-

-

-

0

Accretion of bridge units to redemption value

-

-

-

-

-

-

-

-

-

576

0

0

0

Rights Offering [Member]
Proceeds from equity offering

0

-

-

-

-

-

-

-

-

-

-

-

-

Series C Preferred Stock [Member]
Proceeds from issuance of Series C Preferred Shares

0

-

-

-

-

-

-

-

-

-

-

-

-

Payment of offering costs

0

-

-

-

-

-

-

-

-

-

-

-

-

Series C issuance costs in accounts payable

0

-

-

-

-

-

-

-

-

-

-

-

-